Author: Staff Corvelva
These latest analyses were made possible thanks to the active contribution of the French associations Association Liberté Informations Santé (ALIS), Ligue nationale pour la liberté des vaccinations (LNPLV) and the Australian Association Australian Vaccination-risks Network (AVN), that we thank.
New generation sequencing have become the preferred tool for in-depth analysis in the field of biology and medical science, especially high precision ones. Thanks to these tools, we can approach in a more modern and comprehensive way a number of applications such as de novo sequencing, metagenomic and epigenomic studies, transcriptome sequencing and genome re-sequencing.
This last one (re-sequencing) is largely used in human field, both for research and diagnostic purposes and consists of NGS - Next Generation Sequencing of an entire single genome, to map the Single Nucleotide mutations (SNP), insertions and deletions of more or less long sequences that have occurred in certain locations of the genome, and variations in the number of copies of genomic portions/genes (CNV, Copy Number Variants).
This procedure helps to understand the development mechanism of some pathologies, in order to identify the directions for a future clinical treatment as in the case of cancer for example. Indeed, by this method the genetic heritage of a cancer patient can be fully decoded in both normal and cancerous tissue, thus allowing us to comprehend what exactly has changed within the genome, and, if possible, how to intervene with targeted measures.
The re-sequencing procedure requires that the DNA of an individual is mechanically broken into small dimension fragments (400-500 base pairs) and artificial DNA parts named adapters are tied to these fragments; adapters make it possible to tie the human DNA fragments to a glass surface on which the bases reading (A, C, G, T) is performed. The DNA base pairs reading takes place by means of chemical reactions, namely the incorporation of nucleotides that have been marked by fluorescent molecules. The million sequences (reads) thus obtained are then mapped on the human reference genome by specific software and all the variants are identified comparing the analyzed genome with the reference genome.
This same procedure has been performed on the human genome in Priorix® Tetra lot n. A71CB256A, genome which belongs to cell line MRC-5 (of fetal origin); the work has been carried out by a company in the USA, that routinely deals with human genome re-sequencing analysis. *
*the name of the laboratory that has performed the analysis will be included in the next formal complaint we will file at the Public Prosecutor of Rome and as well at the Italian and European regulatory bodies. The associations who are filing the analysis funded by Corvelva will be promptly kept up to date with these shocking results too. We are no denying that we feel, especially as parents, distressed by these results we are reporting - as if what we have found out so far was not enough to worry about.
During our September 18 debate, Spectrum TV host Renee Eng asked Kaiser’s, Dr. Robert Riewerts, how many vaccine injuries he had seen during his 30 years as a Pediatrician. His answer: “None, not a single one.”
Slide 1. A 2010 HHS pilot study by the AHCR.
Slide 1 shows a 2010 U.S. Health and Human Services (HHS) pilot study by the Federal Agency for Health Care Research (AHCR) to test the efficiency of a state-of-the-art machine counting (AI) system on data records from the Harvard Pilgrim HMO. Those government researchers found that 2.6% of vaccination resulted in injuries—a ratio one for every 39 vaccines administered. The same study found that typical clinicians see 1.3 vaccine injuries per month.
Author: The Corvelva Team
The Italian vaccine research and advocacy organization Corvelva recently released new data regarding the use of aborted fetal cell lines in vaccines. The research reports the results produced from the MRC 5 cell line analysis, particularly the one contained in GlaxoSmithKline’s tetravalent measles-mumps-rubella-chickenpox (MMRV) vaccine.